Commentary on “Immunosuppressant drugs for myasthenia gravis”
- Maria Grazia Celani,
- Peter Sandercock,
- Graeme Hankey,
- Cochrane Neurological Network
- Dr Maria Grazia Celani, Dipartimento di medicina Servizio per le Mt Cerebrovascolari via Guerra 17, 06127 Perugia, Italy; mgcelani{at}iol.it
- Received 14 August 2008
- Revised 14 August 2008
- Accepted 18 August 2008
The choice of treatments for this chronic, disabling yet rare disorder is limited and founded on a weak evidence base. The conclusion that corticosteroid treatment offers significant short-term benefit is based on sources of evidence …
